Athira Pharma (Nasdaq:ATHA) - 주가, 뉴스 및 분석

ATHA 주식 개요

는 임상 후기 단계의 바이오 제약 회사로, 신경세포의 건강을 회복하고 신경 퇴화를 늦추는 저분자 물질을 개발하는 데 주력하고 있습니다. 자세한 내용

ATHA 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

cash runway 경력이 1년 미만입니다.

최근 3개월간 주가 변동폭 심해

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

+ 1 더 많은 위험

Athira Pharma, Inc. 경쟁사

IGC Pharma

NYSEAM:IGC

US$25.8m

ALT5 Sigma

NasdaqCM:ALTS

US$28.0m

Lipocine

NasdaqCM:LPCN

US$25.2m

Impact BioMedical

NYSEAM:IBO

US$30.5m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Athira Pharma
과거 주가
현재 주가	US$0.66
52주 최고치	US$4.30
52주 최저치	US$0.41
베타	2.83
11개월 변경	24.59%
3개월 변경 사항	-80.15%
1년 변경 사항	-56.06%
33년 변화	-95.44%
5년 변화	n/a
IPO 이후 변화	-96.15%

최근 뉴스 및 업데이트

Recent updates

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Oct 17

Athira Pharma GAAP EPS of -$0.65

Aug 15

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Aug 09

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Jun 22

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

May 08

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Jan 11

Athira Pharma: What, Exactly, Did The CEO Do?

Jun 29

Athira Pharma falls after the decision to place CEO on temporary leave

Jun 17

Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy

Jun 07

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

May 24

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Feb 08

Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach

Jan 11

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Dec 18

Athira Pharma nabs research grant of $15M from NIH

Dec 08

Athira Pharma reports Q3 results

Nov 12

주주 수익률

	ATHA	US Pharmaceuticals	US 마켓
7D	-7.7%	-1.4%	0.3%
1Y	-56.1%	10.8%	31.1%

수익률 대 산업: ATHA 지난 1년 동안 10.8 %를 반환한 US Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: ATHA 지난 1년 동안 31.1 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ATHA's price volatile compared to industry and market?
ATHA volatility
ATHA Average Weekly Movement	28.3%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

안정적인 주가: ATHA 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ATHA 의 주간 변동성은 지난 1년 동안 18% 에서 28% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
2011	66	Mark Litton	www.athira.com

임상 후기 단계의 바이오 제약 회사인 아티라 파마는 신경세포의 건강을 회복하고 신경 퇴화를 늦추는 저분자 개발에 주력하고 있습니다. 주요 제품 후보로는 건강한 신경계를 위해 신경 영양성 간세포 성장 인자(HGF) 시스템과 그 수용체인 MET를 조절하도록 설계된 저분자 물질인 포스고니메톤(ATH-1017)이 있으며, 알츠하이머병 치료를 위한 LIFT-AD 2/3상 및 ACT-AD 2상 임상시험을 진행 중이고 파킨슨병 치매 및 루이소체 치매 치료를 위한 2상 임상시험을 진행 중입니다. 이 회사의 제품 파이프라인에는 신경병증성 통증 및 신경 퇴행성 질환 치료를 위해 임상 1상 중인 HGF/MET 시스템을 강화하도록 설계된 경구용 뇌투과성 저분자 약물 후보인 ATH-1020과 근위축성 측색 경화증 치료를 위한 전임상 모델인 경구용 저분자 약물 후보인 ATH-1105가 있습니다.

Athira Pharma, Inc. 기본 사항 요약

Athira Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ATHA 기본 통계
시가총액	US$24.69m
수익(TTM)	-US$109.22m
수익(TTM)	n/a

0.0x

P/S 비율

-0.2x

P/E 비율

ATHA 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ATHA 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$109.22m
수익	-US$109.22m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.84
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

ATHA 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ATHA 주식 개요

위험 분석

Athira Pharma, Inc. 경쟁사

NYSEAM:IGC

US$25.8m

NasdaqCM:ALTS

US$28.0m

NasdaqCM:LPCN

US$25.2m

NYSEAM:IBO

US$30.5m

가격 내역 및 성능

최근 뉴스 및 업데이트

Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Price target decreased by 46% to US$4.00

Athira Pharma, Inc. Announces Topline Results from Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma Announces Last Patient Completed Lift-Ad Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer’s Disease

Recent updates

Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Price target decreased by 46% to US$4.00

Athira Pharma, Inc. Announces Topline Results from Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma Announces Last Patient Completed Lift-Ad Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer’s Disease

New major risk - Financial position

Independent Chairwoman of the Board recently bought US$100k worth of stock

Athira Pharma, Inc. Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer

Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Athira Pharma, Inc., Annual General Meeting, May 23, 2024

New minor risk - Market cap size

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer

Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer

Price target increased by 23% to US$9.25

Athira Pharma, Inc. Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-B-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

New minor risk - Market cap size

Athira Pharma, Inc. Appoints Andrew Gengos as Chief Financial Officer

Athira Pharma, Inc. Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease

CFO & Chief Business Officer recently bought US$192k worth of stock

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Athira Pharma, Inc. Announces the Appointment of Andrew Gengos as Chief Business Officer

Athira Pharma, Inc. Announces CFO Changes

Independent Director recently bought US$60k worth of stock

Price target decreased by 33% to US$7.83

Athira Pharma Announces Promotion of Kevin Church to Chief Scientific Officer

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Chief Financial Officer recently bought US$142k worth of stock

Athira Pharma, Inc. Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

Independent Chairwoman of the Board recently bought US$99k worth of stock

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Price target increased to US$11.75

High number of new and inexperienced directors

Athira Pharma Advances Phase 2/3 Lift-Ad Clinical Study of Fosgonimeton in Mild-To Moderate Alzheimer's Patients Following Independent, Unblinded Interim Analysis

Price target increased to US$11.75

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Athira Pharma, Inc. Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients

Athira Pharma GAAP EPS of -$0.65

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

Price target decreased to US$15.40

Athira Pharma, Inc. Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Athira Pharma, Inc. Announces New Board Appointments

Richard A Kayne Issues Letter to Shareholders of Athira Pharma Inc

Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

Richard A Kayne Communicates with Athira Pharma Inc

Richard A Kayne Communicates with Athira Pharma Inc

High number of new and inexperienced directors

Richard A. Kayne Files an Investor Presentation to Shareholders of Athira Pharma

Richard A. Kayne Files an Investor Presentation to Shareholders of Athira Pharma

Richard A. Kayne Provides Information to Shareholders of Athira Pharma Inc

Athira Pharma, Inc., Annual General Meeting, May 19, 2022

Athira Pharma, Inc. Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions

Independent Chairman of the Board recently bought US$105k worth of stock